limbrel and Vascular-Calcification

limbrel has been researched along with Vascular-Calcification* in 1 studies

Other Studies

1 other study(ies) available for limbrel and Vascular-Calcification

Article	Year
Flavocoxid Ameliorates Aortic Calcification Induced by Hypervitaminosis D Cardiovascular drugs and therapy, 2022, Volume: 36, Issue:6 This research was designed to investigate the effects and mechanisms of flavocoxid (FCX) on vascular calcification (VC) in rats.. Compared to untreated VC rats, FCX treatment prevented body weight loss, reduced aortic calcium deposition, restored normal values of SBP, DBP, and HR, and attenuated LV hypertrophy. FCX also improved renal function and ameliorated serum levels of phosphorus, calcium, and ALP in rats with VC. FCX abolished aortic lipid peroxidation in VC rats. Moreover, VC-FCX rats showed marked reductions in aortic levels of Il-1β and osteogenic marker (Runx2) and attenuated aortic expression of TNF-α, iNOS, and MMP-9 proteins compared to untreated VC rats. The expression of the smooth muscle lineage marker α-SMA was greatly enhanced in aortas from VC rats upon FCX treatment.. These findings demonstrate FCX ability to attenuate VDN-induced aortic calcinosis in rats, suggesting its potential for preventing arteiocalcinosis in diabetic patients and those with chronic kidney disease. Topics: Animals; Calcium; Core Binding Factor Alpha 1 Subunit; Matrix Metalloproteinase 9; Nicotine; Nitric Oxide Synthase Type II; Rats; Rats, Sprague-Dawley; Rats, Wistar; Tumor Necrosis Factor-alpha; Vascular Calcification	2022

Article

Year

Flavocoxid Ameliorates Aortic Calcification Induced by Hypervitaminosis D

Cardiovascular drugs and therapy, 2022, Volume: 36, Issue:6

This research was designed to investigate the effects and mechanisms of flavocoxid (FCX) on vascular calcification (VC) in rats.. Compared to untreated VC rats, FCX treatment prevented body weight loss, reduced aortic calcium deposition, restored normal values of SBP, DBP, and HR, and attenuated LV hypertrophy. FCX also improved renal function and ameliorated serum levels of phosphorus, calcium, and ALP in rats with VC. FCX abolished aortic lipid peroxidation in VC rats. Moreover, VC-FCX rats showed marked reductions in aortic levels of Il-1β and osteogenic marker (Runx2) and attenuated aortic expression of TNF-α, iNOS, and MMP-9 proteins compared to untreated VC rats. The expression of the smooth muscle lineage marker α-SMA was greatly enhanced in aortas from VC rats upon FCX treatment.. These findings demonstrate FCX ability to attenuate VDN-induced aortic calcinosis in rats, suggesting its potential for preventing arteiocalcinosis in diabetic patients and those with chronic kidney disease.

Topics: Animals; Calcium; Core Binding Factor Alpha 1 Subunit; Matrix Metalloproteinase 9; Nicotine; Nitric Oxide Synthase Type II; Rats; Rats, Sprague-Dawley; Rats, Wistar; Tumor Necrosis Factor-alpha; Vascular Calcification

2022